Safety, Tolerability & PK of KX2-361 in Subjects with advanced malignancies that are refractory to conventional treatment.
To define the maximum tolerated dose (MTD) of KX2-361 in subjects with advanced refractory malignancies when administered as single and multiple oral doses.
To determine the safety and tolerability of KX2-361 after single and multiple oral doses, in subjects with advanced refractory malignancies.
To characterize the pharmacokinetic profile of KX2-361 after single and multiple oral doses.
To evaluate the activity of KX2-361 in both the Dose Escalation Cohort and the Expansion Cohort of subjects with high-grade glioma.